Dermata Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Details (Tables)

3 Months Ended

Mar. 31, 2023

	March 31,		December 31,
	2023		2022
Prepaid expenses and other current assets:
Prepaid insurance	$	366,314	$	586,407
Prepaid research and development costs		74,807		92,581
Prepaid other		80,867		11,604
Interest receivable		6,358		12,602
Total prepaid expenses and other current assets	$	528,346	$	703,194

Accrued and other current liabilities:
Accrued research and development costs	$	422,597	$	254,787
Accrued compensation and benefits		131,257		170,389
Accrued legal fees		159,929		-
Accrued other		381		756
Total accrued and other current liabilities	$	714,164	$	425,932